查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1606709

數位生物標記市場：按類型、治療領域、應用分類 - 2025-2030 年全球預測

Digital Biomarkers Market by Type (Hardware, Software), Therapeutic Area (Cardiovascular and metabolic disorders (CVMD), Musculoskeletal disorders, Neurological disorders), End-Use - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

數位生物標記市場2023年估值為36.3億美元，預計到2024年將達到43.4億美元，複合年成長率為19.97%，預計到2030年將達到130億美元。

數位生物標記是指透過智慧型手機、穿戴式裝置和其他遠端感測器等數位裝置收集和測量的可量化的生理、行為和身體資料。它透過提供持續、即時監控、實現個人化醫療和預防性健康管理，在醫療保健轉型中發揮關鍵作用。對數位生物標記的需求源於其比傳統方法更可靠、更具成本效益並提供全面見解的潛力。疾病診斷、治療監測和健康管理的應用在製藥、生物技術、醫療保健和學術研究等領域不斷增加。主要最終用途包括慢性病管理、臨床試驗和心理健康評估，這些用途受益於增強的患者資料收集和改善的結果。

主要市場統計
基準年[2023] 36.3億美元
預測年份 [2024] 43.4億美元
預測年份 [2030] 130億美元
複合年成長率（%） 19.97%

市場成長受到數位健康技術進步、慢性病盛行率上升以及對個人化醫療解決方案不斷成長的需求的顯著影響。此外，人工智慧和機器學習的興起正在推動數位生物標記資料的創新分析並提供可行的見解。然而，市場擴張面臨監管挑戰、資料隱私問題以及廣泛檢驗和標準化的需求等障礙。此外，與現有醫療保健系統的整合可能是一個營運挑戰。

開發可互通的平台存在機會，該平台整合了各種數位生物標記，以實現一致的醫療保健策略，並強調互通性和安全性。公司可以利用與科技公司的夥伴關係來增強其資料分析能力，同時優先考慮改善用戶體驗以推動採用。創新領域包括提高感測器的準確性、降低數位設備的成本以及開拓新興國家開拓的市場。此外，透過與學術機構的聯合研究，我們可以引領新生物標記和應用的發展。持續創新和策略規劃可以幫助公司駕馭複雜的數位生物標記環境，實現永續成長，並為全球醫療保健的進步做出有意義的貢獻。

市場動態：揭示快速發展的數位生物標記市場的關鍵市場洞察

數位生物標記市場正在因供需的動態相互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 擴大生物標記測試在慢性病治療的應用
    • 數位生物標記診斷的主要好處
    • 數位生物標記在以病人為中心的藥物開發和精準醫療的應用
  • 市場限制因素
    • 生物標記開發和數位生物標記採用相關的高成本
  • 市場機會
    • 得益於數位生物標記的最新進展，靈活性和定製配置
    • 政府對遠端醫療基礎設施的投資
  • 市場挑戰
    • 與資料檢驗和解釋相關的問題

波特五力：駕馭數位生物標記市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解數位生物標記市場的外部影響

外部宏觀環境因素在塑造數位生物標記市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解數位生物標記市場的競爭狀況

數位生物標記市場的詳細市場佔有率分析可以對供應商的業績進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來發現自己的競爭定位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣數位生物標記市場供應商的績效評估

FPNV 定位矩陣是評估數位生物標記市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議繪製數位生物標記市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對數位生物標記市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 在慢性病治療中增加生物標記檢測的使用
      • 數位生物標記診斷的主要好處
      • 數位生物標記在以病人為中心的藥物開發和精準醫療的應用
    • 抑制因素
      • 與生物標記物開發和數位生物標記物採用相關的高成本
    • 機會
      • 數位生物標記的最新進展實現了更靈活和客製化的配置
      • 政府對遠端醫療基礎設施的投資
    • 任務
      • 與資料檢驗和解釋相關的問題
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章數位生物標記市場：按類型

  • 硬體
    • 感應器
    • 穿戴式裝置
  • 軟體

第7章依治療領域分類的數位生物標記市場

  • 心血管和代謝疾病（CVMD）
  • 肌肉骨骼疾病
  • 神經系統疾病
  • 精神疾病
  • 呼吸系統疾病
  • 睡眠和運動障礙

第8章數位生物標記市場：依最終用途

  • 醫療保健消費者
  • 醫療服務提供方

第9章美洲數位生物標記市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區數位生物標記市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲的數位生物標記市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • ActiGraph, LLC
  • Adherium
  • Akili, Inc.
  • Altoida, Inc.
  • Amgen Inc.
  • Aural Analytics, Inc.
  • Biofourmis Pte. Ltd.
  • Biogen Inc.
  • Brainomix
  • Chugai Pharmaceutical Co., Ltd.
  • Clarigent Health
  • Eli Lilly and Company
  • Empatica Inc.
  • F. Hoffmann-La Roche Ltd.
  • Feel Therapeutics
  • GERO PTE. LTD.
  • Huma Therapeutics Limited
  • IXICO PLC
  • Kinsa Inc.
  • Koneksa Health
  • Medable Inc.
  • Owkin, Inc.
  • Sidekick Health ehf.
  • Verily Life Sciences
  • VivoSense, Inc
Product Code: MRR-5C6F41F5AF45

The Digital Biomarkers Market was valued at USD 3.63 billion in 2023, expected to reach USD 4.34 billion in 2024, and is projected to grow at a CAGR of 19.97%, to USD 13.00 billion by 2030.

Digital biomarkers refer to quantifiable physiological, behavioral, and physical data collected and measured through digital devices like smartphones, wearables, and other remote sensors. They play a critical role in transforming healthcare by providing continuous and real-time monitoring, enabling personalized medicine and proactive health management. The necessity of digital biomarkers arises from their potential to offer more reliable, cost-effective, and comprehensive insights than traditional methods. They are increasingly applied in disease diagnosis, treatment monitoring, and health management across sectors such as pharmaceuticals, biotechnology, healthcare providers, and academic research. Key end-use applications involve chronic disease management, clinical trials, and mental health assessments, which benefit from enhanced patient data collection and improved outcomes.

KEY MARKET STATISTICS
Base Year [2023] USD 3.63 billion
Estimated Year [2024] USD 4.34 billion
Forecast Year [2030] USD 13.00 billion
CAGR (%) 19.97%

Market growth is significantly influenced by technological advancements in digital health, an increasing prevalence of chronic diseases, and a growing demand for personalized healthcare solutions. Furthermore, the rise of artificial intelligence and machine learning is driving innovative analytics of digital biomarker data, providing actionable insights. However, market expansion faces hurdles such as regulatory challenges, data privacy concerns, and the need for extensive validation and standardization. Additionally, integration with existing healthcare systems can pose operational challenges.

Opportunities exist in developing interoperable platforms that integrate various digital biomarkers into cohesive healthcare strategies, emphasizing interoperability and security. Businesses can capitalize on partnerships with technology companies to enhance data analytics capabilities, while prioritizing the enhancement of user experience to encourage adoption. Innovation areas include improving sensor accuracy, reducing costs of digital devices, and exploring untapped markets in emerging economies. Furthermore, leveraging collaborations with academic institutions for research can lead to the development of novel biomarkers and applications. With continuous innovation and strategic planning, companies can navigate the complex landscape of digital biomarkers to achieve sustainable growth and make meaningful contributions to global healthcare advancements.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Digital Biomarkers Market

The Digital Biomarkers Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing usage of biomarkers testing for the treatment of chronic diseases
    • Significant benefits of digital biomarkers diagnosis
    • Applications of digital biomarkers in patient-focused drug development and precision medicine
  • Market Restraints
    • High cost associated with biomarkers development and adoption of digital biomarkers
  • Market Opportunities
    • Recent advancements in digital biomarkers for more flexibility and customized configuration
    • Government investment in telehealth infrastructure
  • Market Challenges
    • Issues associated with data validation and interpretation

Porter's Five Forces: A Strategic Tool for Navigating the Digital Biomarkers Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Digital Biomarkers Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Digital Biomarkers Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Digital Biomarkers Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Digital Biomarkers Market

A detailed market share analysis in the Digital Biomarkers Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Digital Biomarkers Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Digital Biomarkers Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Digital Biomarkers Market

A strategic analysis of the Digital Biomarkers Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Digital Biomarkers Market, highlighting leading vendors and their innovative profiles. These include ActiGraph, LLC, Adherium, Akili, Inc., Altoida, Inc., Amgen Inc., Aural Analytics, Inc., Biofourmis Pte. Ltd., Biogen Inc., Brainomix, Chugai Pharmaceutical Co., Ltd., Clarigent Health, Eli Lilly and Company, Empatica Inc., F. Hoffmann-La Roche Ltd., Feel Therapeutics, GERO PTE. LTD., Huma Therapeutics Limited, IXICO PLC, Kinsa Inc., Koneksa Health, Medable Inc., Owkin, Inc., Sidekick Health ehf., Verily Life Sciences, and VivoSense, Inc.

Market Segmentation & Coverage

This research report categorizes the Digital Biomarkers Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Hardware and Software. The Hardware is further studied across Sensor and Wearable Device.
  • Based on Therapeutic Area, market is studied across Cardiovascular and metabolic disorders (CVMD), Musculoskeletal disorders, Neurological disorders, Psychiatric Disorders, Respiratory Disorders, and Sleep & Movement Disease.
  • Based on End-Use, market is studied across Healthcare Consumers and Healthcare Providers.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing usage of biomarkers testing for the treatment of chronic diseases
      • 5.1.1.2. Significant benefits of digital biomarkers diagnosis
      • 5.1.1.3. Applications of digital biomarkers in patient-focused drug development and precision medicine
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with biomarkers development and adoption of digital biomarkers
    • 5.1.3. Opportunities
      • 5.1.3.1. Recent advancements in digital biomarkers for more flexibility and customized configuration
      • 5.1.3.2. Government investment in telehealth infrastructure
    • 5.1.4. Challenges
      • 5.1.4.1. Issues associated with data validation and interpretation
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Digital Biomarkers Market, by Type

  • 6.1. Introduction
  • 6.2. Hardware
    • 6.2.1. Sensor
    • 6.2.2. Wearable Device
  • 6.3. Software

7. Digital Biomarkers Market, by Therapeutic Area

  • 7.1. Introduction
  • 7.2. Cardiovascular and metabolic disorders (CVMD)
  • 7.3. Musculoskeletal disorders
  • 7.4. Neurological disorders
  • 7.5. Psychiatric Disorders
  • 7.6. Respiratory Disorders
  • 7.7. Sleep & Movement Disease

8. Digital Biomarkers Market, by End-Use

  • 8.1. Introduction
  • 8.2. Healthcare Consumers
  • 8.3. Healthcare Providers

9. Americas Digital Biomarkers Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Digital Biomarkers Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Digital Biomarkers Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. ActiGraph, LLC
  • 2. Adherium
  • 3. Akili, Inc.
  • 4. Altoida, Inc.
  • 5. Amgen Inc.
  • 6. Aural Analytics, Inc.
  • 7. Biofourmis Pte. Ltd.
  • 8. Biogen Inc.
  • 9. Brainomix
  • 10. Chugai Pharmaceutical Co., Ltd.
  • 11. Clarigent Health
  • 12. Eli Lilly and Company
  • 13. Empatica Inc.
  • 14. F. Hoffmann-La Roche Ltd.
  • 15. Feel Therapeutics
  • 16. GERO PTE. LTD.
  • 17. Huma Therapeutics Limited
  • 18. IXICO PLC
  • 19. Kinsa Inc.
  • 20. Koneksa Health
  • 21. Medable Inc.
  • 22. Owkin, Inc.
  • 23. Sidekick Health ehf.
  • 24. Verily Life Sciences
  • 25. VivoSense, Inc

LIST OF FIGURES

  • FIGURE 1. DIGITAL BIOMARKERS MARKET RESEARCH PROCESS
  • FIGURE 2. DIGITAL BIOMARKERS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. DIGITAL BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. DIGITAL BIOMARKERS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. DIGITAL BIOMARKERS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. DIGITAL BIOMARKERS MARKET DYNAMICS
  • TABLE 7. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY SENSOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY WEARABLE DEVICE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY CARDIOVASCULAR AND METABOLIC DISORDERS (CVMD), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY PSYCHIATRIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY RESPIRATORY DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY SLEEP & MOVEMENT DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY HEALTHCARE CONSUMERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL DIGITAL BIOMARKERS MARKET SIZE, BY HEALTHCARE PROVIDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES DIGITAL BIOMARKERS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM DIGITAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM DIGITAL BIOMARKERS MARKET SIZE, BY HARDWARE, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM DIGITAL BIOMARKERS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM DIGITAL BIOMARKERS MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 191. DIGITAL BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 192. DIGITAL BIOMARKERS MARKET, FPNV POSITIONING MATRIX, 2023